SCHEMBL9890728

SCHEMBL9890728

CNC(=O)Cc1cc(Cl)ccc1-c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 1/20 0.46
FFAR4 Q5NUL3 1/20 0.46
SHMT1 P34896 8/20 0.45
SHMT2 P34897 4/20 0.44
PTGDR2 Q9Y5Y4 1/20 0.43
KDM4E B2RXH2 1/20 0.43
GAA P10253 1/20 0.43
HPGD P15428 1/20 0.43
CHRM1 P11229 1/20 0.43
CHRM3 P20309 1/20 0.43
SUCNR1 Q9BXA5 1/20 0.42
ADAMTS4 O75173 1/20 0.41
ADAMTS5 Q9UNA0 1/20 0.41
PLA2G1B P04054 1/20 0.41
HTT P42858 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
ATG4B Q9Y4P1 1/20 0.41
ALDH1A1 P00352 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
CNR1 P21554 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2393525 0.88 PTGDR2 (0.47) FFAR1FFAR4SHMT1SHMT2PTGDR2
SCHEMBL9890729 0.86 HPGD (0.47) FFAR1FFAR4SHMT1SHMT2KDM4E
SCHEMBL9890771 0.86 SHMT1 (0.47) SHMT1CNR1
SCHEMBL9890763 0.84 HDAC7 (0.47) PTGDR2GAAPLA2G1BHTTL3MBTL1
SCHEMBL3738386 0.83 FFAR1 (0.54) FFAR1FFAR4SHMT1SHMT2PTGDR2
SCHEMBL9890782 0.82 PSEN1 (0.45) PTGDR2
SCHEMBL2395342 0.82 PTGDR2 (0.43) PTGDR2KDM4EHPGDHTTL3MBTL1
SCHEMBL2396004 0.82 FFAR1 (0.46) FFAR1FFAR4PTGDR2ALDH1A1SMN1; SMN2
SCHEMBL9890714 0.82 CYP2C19 (0.49) FFAR1FFAR4PTGDR2CHRM1CHRM3
SCHEMBL9890779 0.81 ALDH1A1 (0.44) FFAR1FFAR4PTGDR2KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 FFAR1 223/4885FFAR4 621/4885SHMT1 1479/4885
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 FFAR1 223/4885FFAR4 621/4885SHMT1 1479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.